Results 171 to 180 of about 3,650 (207)
Some of the next articles are maybe not open access.
Anaphylaxis From Depot Medroxyprogesterone Acetate in an Adolescent Girl
Obstetrics & Gynecology, 2011Anaphylaxis postinjection of depot medroxyprogesterone acetate (DMPA) has been rarely reported in adult women.A 16-year-old girl developed anaphylaxis after receiving 150 mg of DMPA intramuscularly. She previously had received four injections of DMPA without any adverse reactions, including two earlier doses from the same lot number.
Lisa, Lestishock +3 more
openaire +2 more sources
Depot Medroxyprogesterone Acetate and Breast Cancer
Drug Safety, 1996Depot medroxyprogesterone acetate (DMPA) has been used worldwide since 1964 as a contraceptive and by 1993 was in use in more than 90 countries. It was licensed for contraceptive use in the US in 1992. One of the reasons for this delay in licensing in the US was the possibility of an increased risk of breast cancer associated with its use.
openaire +2 more sources
Removing the black box warning for depot medroxyprogesterone acetate
Contraception, 2011This commentary explains why the Food and Drug Administration (FDA) should remove the black box warning regarding skeletal health on the package labeling for the injectable contraceptive depot medroxyprogesterone acetate (DMPA). It states that by depriving women of long-term use of this safe effective product this black box warning hurts the public ...
Andrew M, Kaunitz, David A, Grimes
openaire +2 more sources
Depot Medroxyprogesterone Acetate in Teens: A Risk for Bone Health?
Pediatrics, 2000We believe it would be premature and irresponsible to suspend all use of DMPA in adolescents while we wait for these data. To remove this effective and easily administered contraceptive method would likely result in more unwanted pregnancies. The impact of teen pregnancy on the growing skeleton may also take its toll on peak bone mass and the ...
L K, Bachrach, T, Cundy, S M, Ott
openaire +2 more sources
Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism
Contraception, 1991To assess the effects of depot-medroxyprogesterone acetate (DMPA) upon serum lipids and lipoproteins, a comparative study in chronic users and new acceptors was undertaken. Two groups of women of reproductive age were included in the study; group I (n = 8) was formed by new acceptors whereas, group II (n = 14) constituted DMPA users of more than five ...
J, Garza-Flores +6 more
openaire +2 more sources
Premenopausal bone loss and depot medroxyprogesterone acetate administration
International Journal of Gynecology & Obstetrics, 1994A 39-year-old woman on depot medroxyprogesterone acetate for 17 years developed multiple fractures after falling from a stationary horse. Densitometry revealed significant osteopenia. Although the reported patient was a thin, Caucasian woman, she did not have any other significant risk factors for osteoporosis except for a possible state of partial ...
openaire +2 more sources
Bone Density in Long Term Users of Depot Medroxyprogesterone Acetate
Obstetrical & Gynecological Survey, 1998Objective To identify any adverse effect on bone density in long term users of depot medroxyprogesterone acetate (DMPA) for contraception.Design Cross‐sectional measurement of bone density in users with amenorrhoea of more than one year or any woman using DMPA for more than five years.Setting Community Family Planning Clinics in ...
B, Gbolade +4 more
openaire +2 more sources
Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary
Contraception, 1994This review addresses possible associations between depot-medroxy-progesterone acetate (DMPA) and endometrial and epithelial ovarian cancers. Two unexpected endometrial carcinomas were observed at autopsy of rhesus monkeys treated for 10 years with 50 times the human doses of DMPA.
openaire +2 more sources
Pharmacokinetics of depot medroxyprogesterone acetate contraception.
The Journal of reproductive medicine, 1996Depot medroxyprogesterone acetate (DMPA) is an aqueous suspension of 17-acetoxy 6-methyl progestin administered by intramuscular injection for long-term contraception. This highly effective injectable formulation of medroxyprogesterone acetate (MPA) has a prolonged duration of action since the progestin is released slowly from the muscle.
openaire +1 more source